Duct Tape for Warts — Body Handbook

კანი · §396

Duct Tape for Warts

A small square of silver duct tape, left on a common wart for six days, peeled off for a soak-and-file, then reapplied — for up to two months. The remedy your grandmother forwarded you isn't quite the proven thing the internet says, and isn't the joke a dermatologist might call it either. One small pediatric trial says yes, two bigger ones say no, and the wart your immune system has been ignoring resolves on its own about half the time inside a year anyway. So the honest question isn't "does it work" — it's whether trying a five-dollar roll of tape for eight weeks is a smarter first move than a clinic visit, and what to do when those eight weeks are up.

Do · Course Evidence Mixed თავი კანი

The catch worth knowing up front: the spontaneous-resolution rate for a common wart is so high that most home-remedy success stories — duct tape, banana peels, garlic, anything — are partly just calendar pages turning. Eight weeks of a daily-ish tape ritual is cheap, almost zero downside, and a reasonable thing to try before paying anyone in a white coat. If it works, you have a wart-free finger and a five-dollar roll of duct tape that lasts a decade. If it doesn't, salicylic acid from the pharmacy is the better-evidenced next step, and a stubborn or odd-looking lesion is worth a real diagnosis.

A common wart is a small, hyperkeratotic outgrowth on the skin caused by infection of the basal layer with a cutaneous HPV strain. The virus hides cleverly: it produces very little protein in the upper, visible part of the wart, sheds far from the immune system's deeper antigen-presenting cells, and sits there for months or years while the body essentially fails to notice it Sterling et al. 2014. The reason warts disappear is that the immune system eventually does notice — a T-cell response recognises the infected cells, kills them, and the lump fades. Every wart therapy that isn't surgical or freezing is, in effect, an attempt to speed that recognition up.

Duct tape's pitch is that adhesive occlusion plus a weekly debridement does two things at once. First, sealing the wart under a non-breathable strip raises local hydration, softens the keratin, and lets the soak-and-file step shave off a layer of softened tissue each cycle — mechanical debulking. Second, the rubberised adhesive on standard silver duct tape is a known mild irritant; weeks of continuous contact produce a low-grade contact-dermatitis signal, the kind of chronic inflammatory nudge that may be enough to flip the immune system from ignoring the wart to attacking it. That's the same general idea behind cantharidin, intralesional Candida antigen, imiquimod, and the other irritant therapies a dermatologist might reach for — irritate the wart on purpose, so the immune system stops walking past.

Whether the duct-tape version of that irritation actually crosses the threshold to immune clearance, or just keeps a wart moist and macerated until it would have resolved anyway, is the unsettled question. The mechanism is plausible, not proven. There has never been an immunohistochemistry study of taped versus untaped warts in humans.

What the trials actually say

The story is three studies and a Cochrane review, and they don't agree.

The two attempts to replicate it both came up empty. A Dutch trial in 103 primary-school children compared corn-pad-plus-duct-tape against a corn pad alone: 16% versus 6% at six weeks — the tape arm did numerically better, but not by enough to rule out chance at that sample size de Haen et al. 2006. A larger blinded trial in 80 immunocompetent adults compared transparent duct tape against an inert moleskin pad: 21% versus 22% at two months. Identical. And the warts that did clear in the tape arm recurred at six months in three-quarters of cases, against a third in the controls Wenner et al. 2007. The Cochrane group pooled what was available and concluded the evidence is insufficient to recommend duct tape routinely; salicylic acid and clinic cryotherapy carry meaningfully better evidence Kwok et al. 2012.

The complication is that the two negative trials used clear duct tape — acrylic adhesive, engineered for low skin irritation — and the positive trial used standard silver duct tape, rubberised adhesive, much more likely to irritate. If the active ingredient is irritation, the replications may not have tested the same intervention. This is the rescue an optimist reaches for, and it's not a crazy point. It is also untested: no one has yet run a properly blinded silver-tape-versus-sham trial.

And looming over all of it, the confounder that wrecks small trials of any wart remedy: warts disappear on their own a lot. About two-thirds of warts in children resolve within two years without any treatment, half of those inside six months Massing & Epstein 1963. A more recent Dutch cohort of primary-school children found about half had cleared spontaneously within fifteen months Bruggink et al. 2013. A trial that ends at six or eight weeks is reading the early tail of a long curve; a personal anecdote of "I tried X and it worked in a month" is consistent with X doing absolutely nothing.

The honest read of the literature: probably modestly effective in children, probably inert in adults, and the headline 85% number is almost certainly inflated. The British Association of Dermatologists' guidelines treat it as a patient-preference option, not a first-line therapy Sterling et al. 2014. That's about right.

How to actually do it

The protocol everyone is referring to is the one the original 2002 trial used. Use silver duct tape, not clear — both because the only positive trial used silver and because if irritation is the mechanism, the rubberised adhesive is the more credible irritant. Run it for the full eight weeks before deciding it didn't work; most of the wart's resolution, when it happens, is in the back half of the protocol Focht et al. 2002.

The file or pumice you use on a wart should not be reused on healthy skin or another household member — HPV is transmissible by mechanical inoculation, and the whole point of the debridement is that it generates infectious dust.

Where it goes wrong

Four failure modes account for almost everyone who tries this and concludes it doesn't work.

The tape comes off and stays off. Fingers and feet are the worst possible adhesion sites — washing, sweating, shoe friction, dishwater. If the tape is on the wart for two days out of every six, the protocol has effectively not been run. Wrap the strip so a corner is anchored to less-flexed skin, and don't try this during the week you're going kayaking.

You quit at three weeks. The trial's clearance numbers come from the full eight-week run. A wart that hasn't budged at day twenty is the wart the trial would also have shown unchanged at day twenty; abandoning then misses the back half of the resolution curve.

You used the clear roll. The transparent acrylic-adhesive tape is engineered for low skin irritation, which — if irritation is the mechanism — is the opposite of what's wanted. Both replication trials that used clear tape failed to find an effect Wenner et al. 2007 de Haen et al. 2006. Use the standard silver hardware-store kind.

The skin under the tape revolts. Two months of continuous adhesive contact produces erythema, itching, and sometimes an eczematous patch where the tape sat. Roughly a quarter of pediatric subjects in the original trial had some skin reaction; in adults with sensitive or eczema-prone skin, it can be the dominant problem by week three. If the surrounding skin is angrier than the wart, stop and switch approaches.

When not to tape it

A few other situations where this protocol is the wrong tool:

Anything around the genitals, anus, or face. Warts in those areas are caused by different HPV types and managed by a clinician. The skin is also too thin and irritation-prone for the duct-tape approach.
If your immune system is suppressed. Organ-transplant recipients, people on systemic immunosuppressants, or anyone with poorly controlled HIV tends to have warts that are bigger, more numerous, and stubborn to any therapy that relies on the immune system noticing them. See a dermatologist; this isn't the right starting point.
Plantar warts in a foot with reduced sensation. Diabetes with neuropathy, or any cause of numb feet, means maceration or a small blister under the tape can go unnoticed and become a real wound. Stick to clinic care for foot lesions in this case.
Known adhesive allergy. If you've reacted to bandages or athletic tape before, two months of duct tape is going to produce a worse problem than the wart.

What else is on the shelf

If the tape doesn't work — or you're skipping it — the better-evidenced moves, in order of escalating commitment:

Salicylic acid. Over the counter, applied daily as a liquid, gel, or medicated plaster, usually combined with the same weekly soak-and-file routine. The best-evidenced topical for common and plantar warts; the Cochrane pool puts clearance at roughly half of users versus a third on placebo across many trials Kwok et al. 2012. This is what to try if duct tape didn't move the wart in eight weeks.
Cryotherapy at a clinic. A nurse or GP touches the wart with liquid nitrogen, freezing the tissue. Stings, then aches; may blister. Comparable to salicylic acid for hand warts, somewhat less effective for plantar warts. Usually needs several visits spaced two to three weeks apart.
Waiting. A real option for warts that aren't bothering you. About half of children's warts clear in fifteen months without any treatment Bruggink et al. 2013; adult warts are slower but not infinite. If the wart isn't catching on things, isn't visible in a way that bothers you, and isn't growing, doing nothing is defensible.
In-office options for stubborn warts. Cantharidin, intralesional immune-priming injections, imiquimod, pulsed-dye laser, surgical removal. A dermatologist's territory; reserve for warts that have failed conservative treatment over months.

What gets repeated that isn't quite true

"Duct tape clears 85% of warts." That number is one small, unblinded, single-site pediatric trial from 2002 Focht et al. 2002 against an under-dosed cryotherapy comparator, with no placebo arm to subtract spontaneous resolution. The two follow-up trials that tried to confirm it didn't, and the Cochrane group considered the pool inconclusive Kwok et al. 2012. The 85% gets quoted as if it's a settled fact. It isn't.
"I tried it, it worked, therefore it works." Wart-clearance anecdotes are particularly untrustworthy because the underlying base rate is so high — half of pediatric warts go on their own inside fifteen months Bruggink et al. 2013. Anyone trying any home remedy for two months is likely to coincide with a spontaneous resolution. This is also why every weird remedy on the internet — garlic, banana peel, apple cider vinegar — has its own pile of testimonials.
"Any tape will do." Possibly not. The original positive trial used silver duct tape with a rubberised adhesive; the two trials that used clear acrylic-adhesive tape both came up empty. If the irritation matters, the type of tape matters.
"If the cheap remedy didn't work, nothing will." Salicylic acid is also cheap and has substantially better evidence than duct tape Kwok et al. 2012. Duct tape failing isn't a verdict on whether your wart is treatable.

A few neighbouring topics this entry deliberately doesn't touch: genital warts and the HPV strains that cause them (a different infection, a different therapy, a clinician's job), the HPV vaccine and its cancer-prevention case (related virus family, unrelated to the cutaneous warts here), and the in-office side of recalcitrant-wart treatment (cantharidin, intralesional antigen, laser, surgical). The brief here is the kitchen-drawer remedy and the evidence for and against it.

Substance and claimed effects

Duct tape occlusion therapy (DTOT) is the home practice of covering a common cutaneous wart (verruca vulgaris, typically caused by HPV types 1, 2, 4, 27, 57) with a small patch of standard silver-grey duct tape, left in place for several days, periodically removed to debride macerated tissue with a pumice stone or emery board, and reapplied — over a course of up to roughly two months — in the expectation that the wart will resolve. The claim, going back to a 2002 pediatric trial Focht et al. 2002, is that occlusion plus the resulting irritation either provokes a local immune response that clears the underlying HPV infection or mechanically wears the wart down faster than no treatment would. Scope for this entry: the substance (a strip of duct tape, daily-ish self-care), its mechanism (occlusion plus chronic low-grade irritation as a possible immune trigger), its evidence (one positive open-label pediatric RCT, two subsequent negative RCTs, a Cochrane review that finds the evidence weak), its protocol, its skin-irritation failure mode, and the enormous spontaneous-resolution confounder that makes everything in this literature hard to read.

Evidence by addressing question

mechanism

No mechanism for duct tape occlusion has been proven in humans; the candidate explanations are all plausibility arguments adjacent to other irritant therapies.

Occlusion + maceration. Continuous occlusion under an adhesive patch raises local hydration, softens the hyperkeratotic surface, and macerates the stratum corneum. This is what makes the weekly debridement step physically possible — soaking + pumice removes a thin layer of softened wart tissue each cycle. By itself, mechanical debulking is not curative (the HPV-infected basal keratinocytes sit deeper than a pumice reaches), but it reduces wart bulk and may expose viral antigen.

Irritant-induced immune recognition. The mainstream pharmacologic options for recalcitrant warts — cantharidin, intralesional Candida or mumps antigen, imiquimod, squaric acid dibutyl ester (SADBE), diphencyprone — all share the same core idea: chronically irritate the wart so the immune system stops ignoring it. Cutaneous HPV evades immunity by producing very little viral protein in the upper epidermis and shedding antigen far from dermal antigen-presenting cells; immune clearance, when it happens, is cell-mediated and depends on T-cell recognition of HPV-infected keratinocytes Sterling et al. 2014. Adhesive occlusion may produce a similar low-grade contact-dermatitis signal — local cytokine release, dendritic-cell activation, T-cell recruitment — that nudges this recognition along. This is hypothesis, not mechanism in the strict sense: there are no immunohistochemistry studies showing increased T-cell infiltrate under taped warts vs untreated warts in humans.

Note on the mechanism gap. The mechanism story has been written backward from the original positive trial rather than forward from immunology. If duct tape did not also macerate, irritate, and force weekly debridement, the occlusion alone would not be expected to do much — and if irritation is the active ingredient, much sharper irritants exist. The mechanism plausibility is real but weak; it should not be relied on to override negative trial data.

evidence

Three RCTs and one Cochrane review define the literature. They do not agree.

Focht 2002 (positive, pediatric, open-label). The seminal trial. n=51 patients aged 3–22 (median 9) randomized to either silver duct tape applied directly to the wart for up to 2 months (n=26) or to liquid-nitrogen cryotherapy every 2–3 weeks (n=25, max 6 treatments). Duct tape: 22/26 (85%) had complete resolution within 2 months. Cryotherapy: 15/25 (60%). p=0.05 Focht et al. 2002. The protocol was the now-standard one: tape for 6 days, remove, soak + debride with pumice, leave open overnight, reapply for another 6 days. Limitations: small, single-site, no blinding (impossible with the comparator), no placebo arm, no spontaneous-resolution control, the cryotherapy arm was undertreated (typical pediatric cryotherapy goes to ≥10 treatments not 6), and the cohort skewed young where spontaneous resolution is already high. The 85% number drove the popularization of the remedy.

Wenner 2007 (negative, adult, double-blind). n=80 immunocompetent adults aged 18–60 randomized to 8 weeks of transparent (clear) duct tape vs moleskin pad with no adhesive, both applied identically. Resolution at 2 months: 21% tape vs 22% control. No significant difference. Recurrence within 6 months was actually higher in the tape arm (75% vs 33% of those who initially cleared) Wenner et al. 2007. Used clear duct tape (different adhesive chemistry from the silver original).

de Haen 2006 (negative, pediatric). n=103 Dutch primary-school children aged 4–12 randomized to corn pad + duct tape vs corn pad alone. Resolution at 6 weeks: 16% tape vs 6% control. Difference (10 percentage points) did not reach statistical significance in this sample (95% CI roughly −2 to +22) de Haen et al. 2006. Direction of effect favours tape but is consistent with chance at this sample size.

Cochrane review 2012. Kwok et al. pooled the duct-tape trials and concluded the evidence for DTOT is of insufficient quality and quantity to support its routine recommendation; topical salicylic acid and cryotherapy carry meaningfully stronger evidence as first-line therapies for cutaneous warts Kwok et al. 2012. The British Association of Dermatologists' 2014 guideline reaches the same conclusion: DTOT may be considered as adjunctive or patient-preference therapy but should not displace salicylic acid or cryotherapy where those are available Sterling et al. 2014.

The clear-tape / silver-tape confound. The one trial that worked used silver duct tape (rubberised adhesive, woven fabric backing). Both replication attempts used clear duct tape (acrylic adhesive). If the active ingredient is adhesive chemistry — rubberised glue being a known mild irritant; acrylic glue being engineered for low irritation — then the trials are not measuring the same intervention. This has been raised in correspondence around Wenner 2007 and remains a live possibility, not a settled mechanism.

The spontaneous-resolution confound. Cutaneous warts resolve without treatment at a rate that wrecks small trials. Massing & Epstein 1963 followed 1,000 institutionalized children with untreated warts: about two-thirds resolved within 2 years, half of those within 6 months Massing & Epstein 1963. Bruggink et al. 2013 followed 366 Dutch primary-school children: 52% had cleared spontaneously within 15 months Bruggink et al. 2013. Any trial with a 6–8 week endpoint is sampling the early tail of a long resolution curve; modest differences between arms are easily either real or noise.

protocol

The Focht 2002 protocol is the de facto standard Focht et al. 2002:

Cut a piece of silver duct tape slightly larger than the wart.
Apply directly over the wart, pressing the adhesive down firmly.
Leave in place for 6 days. Replace if it falls off.
On day 7, remove the tape, soak the area in warm water for ~15 minutes, then debride the softened surface tissue with a pumice stone or emery board until smooth.
Leave the area open to air overnight.
The next morning, apply a fresh piece of tape and repeat.
Continue cycles for up to 2 months. If no improvement by 2 months, the protocol has not worked; escalate.

Practical clinical advice diverges on a few points: pediatric dermatology generally accepts the 6-day cycle; some practitioners use overnight-only application to reduce skin irritation in children with sensitive skin. Filing tools (emery board, pumice) used on warts should not be reused on healthy skin — HPV is transmissible via mechanical inoculation.

contraindications

Duct tape is mechanically benign; the contraindications are mostly about whether the underlying lesion is actually a common wart and whether the patient can mount the immune response the therapy depends on.

Lesion is not a wart. Several skin lesions mimic verruca vulgaris: seborrheic keratosis, molluscum contagiosum, corns (clavi), amelanotic melanoma, squamous cell carcinoma. A "wart" that is bleeding spontaneously, growing rapidly, changing pigment, ulcerating, or unresponsive to several months of any therapy needs dermatologic evaluation — biopsy a lesion that does not behave like a wart, do not tape it for months Sterling et al. 2014.
Genital, perianal, and facial warts: not appropriate. Anogenital HPV (types 6, 11, 16, 18 etc.) is treated by a clinician; DTOT is not indicated and the skin is too thin and irritation-prone for the protocol.
Immunocompromise. Solid-organ transplant recipients, HIV with poor viral control, and patients on systemic immunosuppression have impaired cell-mediated clearance of HPV and warts that are larger, more numerous, and frequently treatment-resistant. DTOT in this population has not been studied and the underlying immune mechanism may not be available; refer to dermatology.
Diabetes with neuropathy. Plantar warts in patients with reduced sensation risk going unnoticed if the tape causes maceration, blistering, or secondary infection. The same caution as any home foot care in this group: avoid.
Adhesive-allergic or eczema-prone skin. The procedure depends on weeks of continuous adhesive contact; patients with known acrylate or rubber-adhesive contact dermatitis will develop a worse problem than the wart.

misconceptions

"Duct tape is a proven wart cure." The remedy is widely shared as if the science is settled. It is not. One positive open-label pediatric trial, two negative blinded trials, and a Cochrane review concluding the evidence is insufficient Kwok et al. 2012.
"It worked, so it must work." The base rate of spontaneous wart resolution is high enough that any individual success story is consistent with the wart having cleared on its own Bruggink et al. 2013. This is the dominant epistemic problem in the home-remedy literature for warts.
"Any kind of tape works." The original trial used silver duct tape with a rubberised adhesive; the trials that failed to replicate used clear duct tape with acrylic adhesive. If the active ingredient is adhesive irritation, the substitution may matter.
"If duct tape didn't work, nothing will." Salicylic acid (over the counter) and cryotherapy (clinic) both have meaningfully stronger evidence and should be the next steps if a wart is bothersome Kwok et al. 2012.

failure-modes

Tape that won't stay on. Fingers and feet are high-flex, high-wash, high-friction sites. Tape peels off in the shower, in dishwashing, in shoes. Failed adhesion means the protocol effectively didn't happen.
Skin irritation, contact dermatitis, blistering. Weeks of continuous adhesive contact produce erythema, itching, eczematous dermatitis, and occasionally friction blisters at the tape margins. Roughly a quarter of pediatric subjects in the Focht trial had some reportable skin reaction, and irritation is the most common reason cited for protocol abandonment.
Premature judgment of failure. The Focht protocol runs 2 months. A 2-week try-and-abandon misses the trial's own time-to-resolution distribution.
Clear duct tape instead of silver. Possibly inert if the rubber-vs-acrylic adhesive distinction is what matters.
Treating a lesion that isn't a wart. Months of tape on a misdiagnosed lesion (corn, molluscum, early skin cancer) delays the right diagnosis.

alternatives

Salicylic acid (over the counter). The best-evidenced topical therapy for common and plantar warts; daily application of 15–40% salicylic acid for up to 12 weeks. Cochrane pooled clearance rate roughly 50% vs 30% placebo across multiple trials Kwok et al. 2012. Often combined with weekly debridement (the same soak-and-pumice as DTOT).
Cryotherapy. Liquid nitrogen applied by a clinician every 2–3 weeks; comparable efficacy to salicylic acid for hand warts, somewhat less for plantar warts. Painful, can blister, may require several treatments.
Watchful waiting. Given that half of pediatric warts resolve within 15 months unaided Bruggink et al. 2013, doing nothing is a defensible option for non-bothersome warts in children and in adults willing to wait.
In-office options for recalcitrant warts. Cantharidin, intralesional Candida antigen, imiquimod, pulsed-dye laser, surgical curettage. All require a dermatologist; reserve for warts that have failed conservative treatment over months.

practicalities

A roll of standard silver duct tape costs around five dollars and lasts indefinitely for this purpose. Total time investment: a few seconds to apply, a 15-minute soak-and-file once a week. Most of the burden is the visible silver patch on a finger for two months — easy to ignore at home, more conspicuous at work or in photos. For a plantar wart, the tape is invisible inside a shoe and the bigger logistical issue is keeping the tape adhered through sweat and friction.

payoff

If the treatment works, a common wart that has been present for months resolves over roughly 6–8 weeks, with the visible wart gradually flattening and disappearing. Recurrence is possible — Wenner 2007 saw 75% recurrence at 6 months in the tape arm subset that initially cleared Wenner et al. 2007 — but a single resolved wart in someone whose immune system is now primed against that HPV serotype tends to stay resolved. No felt-experience payoff beyond the lesion itself going away.

out-of-scope

Anogenital warts and HPV vaccination (different HPV types, different therapy, different stakes).
The full pharmacopoeia of in-office wart treatments (immunotherapy, laser, surgical).
HPV-associated cancers (cervical, anal, oropharyngeal) — unrelated to the cutaneous HPV serotypes that cause common warts.

The credibility range

Optimist case. The original Focht 2002 trial showed a 25-percentage-point absolute advantage over cryotherapy in children — a large effect for a near-free intervention Focht et al. 2002. The mechanism is biologically reasonable: occlusion + irritation mirrors the irritant-immune-recall approach already validated for cantharidin and intralesional antigens. The two negative replications both used a different tape product (clear acrylic-adhesive vs silver rubberised-adhesive), so they may not have actually tested the same intervention. The community signal — decades of parents reporting success — is large, consistent, and predates the publication. The de Haen 2006 trial's numerical direction favoured tape (16% vs 6%) and only failed for power reasons de Haen et al. 2006. The downside risk is essentially zero (a small patch of tape and some skin irritation), so any positive base-rate-shift is a clinical win.

Skeptic case. The one positive trial was small, open-label, single-site, used an undertreated comparator (6 cryotherapy sessions when 10+ is typical), and had no placebo arm to control for the very high spontaneous-resolution rate in the pediatric population sampled. The two attempts at replication, both blinded and one placebo-controlled, both negative. The Cochrane review concluded the evidence is insufficient Kwok et al. 2012. The mechanism is post hoc — if irritation is the lever, why not use a known irritant? The silver-vs-clear-tape rescue is unfalsified, not validated. And in immunocompetent adults, where the spontaneous resolution rate is lower, the one trial that tested DTOT showed exactly the null result you would expect of an inert intervention Wenner et al. 2007.

Author's call. The honest read: probably modestly effective in children, probably inert in adults, and the original 85% number is almost certainly inflated by spontaneous resolution. Lands at evidence 2 / controversy 3. The intervention is so cheap, so safe, and so easy to start with that "try it first for 6–8 weeks before escalating to salicylic acid or a clinic visit" is reasonable for a non-bothersome wart, even if its specific effect over baseline is small. The article should not present it as proven, should explicitly name the spontaneous-resolution confounder, and should make clear that salicylic acid and cryotherapy are the better-evidenced second steps.

Stakeholder and incentive map

Pediatric primary care. Loves DTOT because it gives parents something benign to do, defers a child's first cryotherapy experience (painful, frightening), and the worst case is "didn't work, try the next thing." Practitioner enthusiasm carries the remedy beyond what the literature supports.
Dermatology. Generally lukewarm; guidelines acknowledge DTOT as an option but rank it below salicylic acid and cryotherapy Sterling et al. 2014. No professional society endorses it as first-line.
Consumer media. A perennial "weird home remedy that works" story; runs every few years, often citing Focht 2002 without the subsequent negative replications. This shapes lay perception.
Commercial. Essentially none. Duct tape is a commodity; no industry funds either the promotion or the rebuttal. This absence of commercial incentive is unusual for a popular intervention and is the main reason the evidence base is small — nobody has paid for a large definitive trial.

Population variability

Age. Pediatric warts have a substantially higher spontaneous-resolution rate than adult warts Massing & Epstein 1963 Bruggink et al. 2013; intervention effects ride on top of this. The positive trial was pediatric; the clearly negative trial was adult. This may be the real population split.
Immune status. Immunocompetent vs immunosuppressed is the largest single modifier. Transplant recipients and HIV-positive patients with low CD4 counts have warts that are larger, more numerous, more persistent, and unlikely to respond to any irritant-immune approach.
Wart location. Hand and finger warts respond best to topicals generally; plantar warts (thicker stratum corneum) are more stubborn for any topical including DTOT. Periungual and subungual warts are particularly resistant.
Wart duration. Older, more keratotic warts respond worse than fresh ones to any topical therapy, DTOT included.

Knowledge gaps

No adequately powered, blinded, placebo-controlled trial of silver duct tape (rubberised adhesive) has ever been performed. The trials that tested silver tape were not blinded; the trials that were blinded did not use silver tape.
No mechanistic study (immunohistochemistry, cytokine profile) of taped vs untaped warts in humans.
No head-to-head trial of duct tape vs salicylic acid in either age group — the two cheapest home options are uncompared.
No longitudinal recurrence data beyond Wenner's 6 months.
What would change the author's call: a properly blinded silver-tape vs sham-tape trial in adults at n≥300, or a clean head-to-head against salicylic acid powered to detect a 10-point absolute difference.

Scope vs brief. The brief named the substance and five named consequences (HPV immune clearance, occlusion-and-irritation mechanism, the spontaneous-resolution confounder, skin irritation, conflicting trials). The article covers all five — mechanism and immune story together in mechanism, the trial conflict and the spontaneous-resolution confounder together in evidence, skin irritation in failure-modes, with no scoping narrowing.

Rating difficulty: evidence vs controversy. The hard call was the evidence score. One positive open-label trial, two negative blinded ones, a Cochrane review calling it thin — that's a clean 2. Controversy is the more interesting axis: pediatric primary care and lay community still actively recommend it; dermatology guidelines treat it as patient-preference-only. Scored 3 rather than 2 because the silver-vs-clear-tape adhesive confound is still a live, unresolved technical disagreement, not just a stale taste preference.

Mood scored 1, not 0. Tempted to zero this out — a wart isn't depression. Held the 1 because visible hand warts genuinely carry self-consciousness for many adults and clearing one is a real, if small, relief. The pitch leans on that ("the hand you keep half-hiding in meetings").

Dream narrative written despite score <40. Overall score lands around 14, well under the 40 obligation threshold. Wrote one anyway on the relief / not-being-conned lever — the honest hook here is debunking-plus-permission, and giving the dek some narrative to draw from let it lead with relief rather than trial design. See set_dream_narrative.

No stakes or payoff section. The substance is too low-stakes for either to earn its place. The "what if you ignore it" is "the wart is still there" — not a felt-experience forecast worth a whole section. Folded the small wins (no clinic copay, the lifted self-consciousness) into the dek, highlights, and pitches instead.

No contraindications tokens set. The closed vocabulary doesn't have a fitting token — "immunocompromise" isn't in the list, "diabetes-medication" is about being on the meds, not about neuropathy. The real contraindications (not-actually-a-wart, immunosuppression, neuropathic foot, adhesive allergy, anogenital sites) live in the body's contraindications section instead.

Future links worth wiring. Salicylic acid for warts (separate entry candidate; better-evidenced first-line topical and the natural escalation step), clinic cryotherapy, the HPV vaccine. None exist yet in the catalogue; this entry should cross-link to them once they do.

Separate-entry candidates. A standalone salicylic acid for cutaneous warts entry is the most obviously missing neighbour — stronger evidence base, same audience, same protocol shape (soak and file).